Castle Biosciences (NASDAQ:CSTL) Insider Tobin Juvenal Sells 20,863 Shares

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Tobin Juvenal sold 20,863 shares of the firm’s stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $25.24, for a total transaction of $526,582.12. Following the completion of the transaction, the insider directly owned 86,825 shares of the company’s stock, valued at approximately $2,191,463. The trade was a 19.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Castle Biosciences Price Performance

Shares of Castle Biosciences stock traded up $0.27 during trading on Monday, hitting $25.83. The stock had a trading volume of 331,478 shares, compared to its average volume of 422,371. The company has a current ratio of 5.26, a quick ratio of 5.11 and a debt-to-equity ratio of 0.02. Castle Biosciences, Inc. has a 12 month low of $14.59 and a 12 month high of $44.28. The firm has a market cap of $767.93 million, a price-to-earnings ratio of -30.39 and a beta of 1.09. The business’s 50-day moving average is $34.64 and its 200 day moving average is $31.75.

Castle Biosciences (NASDAQ:CSTL) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.15. Castle Biosciences had a negative return on equity of 0.89% and a negative net margin of 7.02%.The company had revenue of $81.88 million during the quarter, compared to analyst estimates of $81.19 million. As a group, sell-side analysts anticipate that Castle Biosciences, Inc. will post 0.44 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have recently issued reports on the company. BTIG Research lifted their price target on Castle Biosciences from $38.00 to $50.00 and gave the company a “buy” rating in a research report on Friday, December 12th. Morgan Stanley raised shares of Castle Biosciences to a “buy” rating in a research note on Monday, March 2nd. KeyCorp reiterated an “overweight” rating and set a $50.00 target price on shares of Castle Biosciences in a research report on Thursday, January 29th. Weiss Ratings reissued a “sell (d)” rating on shares of Castle Biosciences in a report on Monday, December 29th. Finally, Canaccord Genuity Group raised their price objective on shares of Castle Biosciences from $37.00 to $50.00 and gave the company a “buy” rating in a research report on Monday, December 22nd. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $47.57.

Hedge Funds Weigh In On Castle Biosciences

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Amundi raised its holdings in shares of Castle Biosciences by 15,811.5% during the 1st quarter. Amundi now owns 4,137 shares of the company’s stock valued at $79,000 after buying an additional 4,111 shares in the last quarter. AQR Capital Management LLC boosted its stake in Castle Biosciences by 548.9% in the first quarter. AQR Capital Management LLC now owns 137,022 shares of the company’s stock worth $2,743,000 after buying an additional 115,907 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Castle Biosciences by 4.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,441 shares of the company’s stock worth $309,000 after buying an additional 655 shares in the last quarter. Jones Financial Companies Lllp grew its position in Castle Biosciences by 10,592.0% during the first quarter. Jones Financial Companies Lllp now owns 2,673 shares of the company’s stock valued at $54,000 after acquiring an additional 2,648 shares during the last quarter. Finally, Envestnet Asset Management Inc. grew its position in Castle Biosciences by 1.0% during the second quarter. Envestnet Asset Management Inc. now owns 70,478 shares of the company’s stock valued at $1,439,000 after acquiring an additional 707 shares during the last quarter. 92.60% of the stock is currently owned by hedge funds and other institutional investors.

About Castle Biosciences

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.